Skip to main content

Vaccination In Atherosclerosis

Objective

"Cardiovascular disease (CVD) is still a leading cause of death in the European Union (EU) accounting for nearly half of all deaths in Europe (48%). In addition, CVD complications lead to a vast number of hospitalizations and thus to a great burden of health care costs in the EU. Atherosclerosis and its final complication, plaque rupture and subsequent infarct in heart or brain, is the main underlying pathology of CVD and atherosclerosis is responsible for 70% of all cases of CVD. Extensive studies into the pathology of atherosclerosis show that its etiology is found in a combination of dyslipidemia and a related inflammatory response with an established autoimmune component, while the major cause of acute CVD events, plaque rupture, due to an inflammatory destabilization of the atherosclerotic lesion. CVD is therefore an autoimmune-like disease in the context of a metabolic disease. Thus far, therapeutic approaches in CVD have been focused at normalizing dyslipidemia in order to lower plasma cholesterol. Statins and additional surgical approaches such as angioplasty have achieved a 30% risk reduction for CVD during the last 10-15 years. However, additional approaches to improve the treatment of dyslipidemia by for instance improving the level of the anti-atherogenic lipoprotein HDL have failed in a number of clinical trials. This implicates that new therapeutic approaches are urgently needed to narrow down the remaining 70% risk for CVD. We aim to develop a new immunomodulatory treatment, a therapeutic vaccine that permanently restores the immune balance within the arterial wall by inhibiting the inflammatory responses during atherosclerosis. The VIA consortium aims to develop a vaccine, dissect the immune pathways underlying the beneficial effect of the vaccine, optimize the vaccine, test its safety and perform a phase I clinical trial using the atheroprotective vaccine. The vaccine is foreseen to result in a substantial lowering of the risk for CVD."

Field of science

  • /medical and health sciences/basic medicine/pathology
  • /medical and health sciences/clinical medicine/cardiology/cardiovascular diseases/arteriosclerosis

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UNIVERSITEIT LEIDEN
Address
Rapenburg 70
2311 EZ Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 158 815,50
Administrative Contact
Ton Brouwer (Mr.)

Participants (11)

MAX IV Laboratory, Lund University
Sweden
EU contribution
€ 640 000
Address
Paradisgatan 5C
22100 Lund
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jacqueline Postma (Dr.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 565 001
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Caroline Hamilton (Mrs.)
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 451 972
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Christoph Binder (Prof.)
GOETEBORGS UNIVERSITET
Sweden
EU contribution
€ 452 550
Address
Vasaparken
405 30 Goeteborg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ellen Rydberg (Dr.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 452 254
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
Giuseppina Caligiuri (Dr.)
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 452 500
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Renata Schaeffer (Ms.)
POLYGENE AG

Participation ended

Switzerland
EU contribution
€ 5 920,30
Address
Riedmattstrasse 9
8153 Rümlang
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Doron Shmerling (Dr.)
CARDIOVAX LLC
United States
EU contribution
€ 527 500
Address
Glenbarr Avenue 10345
90064 Los Angeles Ca
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mark Carvlin (Dr.)
STICHTING CENTRE FOR HUMAN DRUG RESEARCH
Netherlands
EU contribution
€ 731 000,20
Address
Zernikedreef 10
2333 CL Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Koos Burggraaf (Prof.)
BRENNTAG NORDIC AS/BRENNTAG BIOSECTOR AS
Denmark
EU contribution
€ 302 340
Address
Strandvejen 104 A
2900 Hellerup
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jan Olesen (Mr.)
PROBIOGEN AG
Germany
EU contribution
€ 254 380
Address
Goethestrasse 54
13086 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Andrea Hauptmann (Mrs.)